ORPHA:314777
Familial isolated pituitary adenoma
Also known as: FIPA
Publications
385
71.8th percentile
Trials
0
Interventional, condition-specific
Researchers
1,072
Distinct authors in sample
Gene link
—
Readiness
4/6
Stages with a signal
Clinical definition (Orphanet)
A rare, endocrine tumor characterized by a benign pituitary adenoma that is either secreting (e.g. prolactin, growth hormone, thyroid stimulating hormone) or non-secreting. Symptoms may occur due to either the hormonal hypersecretion and/or the mass effect of the lesion on local structures in the brain.
How rare: How common this is has not been clearly measured.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0017824
- UMLS:C2676191
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
4/6 stages with a signal
No specific-condition interventional trial, but broader-category trials exist — discuss eligibility with a clinician.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
385 matched papers (247 in last 10 years) Source
- Phenotype characterisedPresent
166 HPO annotations (e.g. Truncal obesity; Immunodeficiency; Increased circulating ACTH level) Source
- Animal modelPresent
3 genotype models (Mus musculus) Source
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialPartial
None under the specific name; 418 for broader category adenoma
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
166
Associated phenotypes · MONDO:0017824
- Truncal obesity
- Immunodeficiency
- Increased circulating ACTH level
- Proximal amyotrophy
- Moon facies
Showing 5 of 166 — open Monarch for the full list.
Animal models (Monarch / Alliance)
3
Model associations linked to this Mondo ID
- Men1tm1Zqw/Men1+ [background:] involves: 129/Sv * 129P2/OlaHsd·MGI:5009321·Mus musculus
- Tg(PyLT)1Vb/0 [background:] Not Specified·MGI:5805519·Mus musculus
- Tg(Prl-EGFR)#Sme/0 [background:] Not Specified·MGI:5696742·Mus musculus
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
No drugs or clinical candidates returned for this Mondo ID on Open Targets.
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
385
385 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
385 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
247 in the last 10 years · medium confidence · 71.8th percentile (publications denominator)
Phrase hits: 385 · MeSH hits: 0
Who's working on it?
1,072
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01
- 02Korbonits M21 papers · 2025
Centre for Endocrinology, Barts and The London School of Medicine, London, EC1M 6BQ, UK. m.korbonits@qmul.ac.uk.
Papers in Europe PMC - 03Daly AF19 papers · 2026
Department of Endocrinology, Centre Hospitalier Universitaire de Liège, University of Liège, Domaine Universitaire du Sart-Tilman, Liège, Belgium.
Papers in Europe PMC - 04Hernández-Ramírez LC14 papers · 2026
Centre for Endocrinology, Barts and The London School of Medicine, London, EC1M 6BQ, UK.
Papers in Europe PMC - 05Stratakis CA13 papers · 2023
Section on Endocrinology and Genetics, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), NIH, Bethesda, MD, 20892, USA.
Papers in Europe PMC - 06Trivellin G11 papers · 2024
Section on Endocrinology and Genetics, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), NIH, Bethesda, MD, 20892, USA.
Papers in Europe PMC - 07Gadelha MR6 papers · 2025
Division of Endocrinology, Clementino Fraga Filho University Hospital, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.
Papers in Europe PMC - 08Chittiboina P5 papers · 2025
Neurosurgery Unit for Pituitary and Inheritable Diseases and Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH), Bethesda, MD, United States.
Papers in Europe PMC - 09Doglietto F5 papers · 2025
Facoltà di Medicina e Chirurgia, Università Cattolica del Sacro Cuore, 20123 Rome, Italy.
Papers in Europe PMC - 10Faucz FR5 papers · 2023
Section on Endocrinology and Genetics, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health (NIH), Bethesda, MD, United States.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name. 2 observational studies did — shown below because natural-history and cohort work can be an important step toward a trial. 418 trials are registered for adenoma, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 11 September 2026 · last trial check 11 September 2026
No matched interventional trials. This is true for 77.2% of diseases in the trials denominator (5501 of 7126). Here are the researchers publishing on it.
medium confidence · 38.6th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
418 interventional trials matched adenoma, the broader category — listed below. Those studies are not counted in the condition-specific total.
Broader category: adenoma
418
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT07307547·NOT YET RECRUITING·Efficacy of AI-Assisted Colonoscopy for Screening Colorectal Neoplasia (AI-COLOSCREEN)
Conditions: Colorectal Neoplasms · Colonic Polyp · Adenoma · Colorectal Cancer·Matched via name phrase
- NCT07034859·ENROLLING BY INVITATION·Cabergoline in the Management of Nonfunctioning Pituitary Adenoma
Conditions: Pituitary Adenoma · MRI · RCT·Matched via name phrase
- NCT07297745·NOT YET RECRUITING·Trial of Aldosterone-hybrid SteRoid for Guiding curablE Treatment of Primary Aldosteronism (TARGET-PA)
Conditions: Hyperaldosteronism; Primary · Primary Aldosteronism Due to Aldosterone Producing Adenoma·Matched via name phrase
- NCT07446543·NOT YET RECRUITING·Effect of Negative-Pressure Drainage Versus Pancreatic Duct Stenting for Preventing Pancreatitis After Endoscopic Papillectomy for Duodenal Papillary Tumors
Conditions: Ampulla of Vater Neoplasms · Ampullary Adenoma · Ampullary Carcinoma·Matched via name phrase
- NCT07043010·NOT YET RECRUITING·WHITE CAP: Intra-operative Parathyroid Tissue Sensor (PTS)-Guided Assessment of Parathyroid Viability and Surgical Decision-Making
Conditions: Hyperparathyroidism, Primary · Parathyroid Neoplasms · Parathyroid Adenoma · Hypocalcemia·Matched via name phrase
- NCT06490757·RECRUITING·A Phase 2 Open-label Single-arm Trial of JAK1 Inhibitor for the Treatment of Large Inflammatory Hepatocellular Adenomas
Conditions: Inflammatory Hepatocellular Adenoma·Matched via name phrase
- NCT06297473·ENROLLING BY INVITATION·Physical Attendance Versus Telephone or Video Follow-up in Patients With Non-functioning Pituitary Tumors.
Conditions: Non-Functional Pituitary Adenoma·Matched via name phrase
- NCT05727605·RECRUITING·Neurocognition After Radiotherapy in CNS- and Skull-base Tumors
Conditions: Cognition · Brain Tumor · Magnetic Resonance Imaging · Meningioma·Matched via name phrase
- NCT07115992·RECRUITING·Efficacy and Safety of Radical Prostatectomy (RP) With or Without Salvage Radiotherapy Versus RP With Extended Pelvic Lymph Node Dissection for Localized Intermediate- and High-risk Prostate Cancer With a Briganti Nomogram≥7%
Conditions: Prostate Cancer · Prostate Adenoma·Matched via name phrase
- NCT07146165·RECRUITING·Clinical Evaluation of a New Platform for Bi-manual Endoscopic Resection in the Rectum and Sigma (EndoTEM)
Conditions: Adenoma Colon Polyp · Adenoma Colon·Matched via name phrase
- NCT07387419·RECRUITING·Ultradian Steroid Rhythms in Adrenal Incidentalomas
Conditions: Mild Autonomous Cortisol Secretion Adenoma · Non Secreting Adenoma·Matched via name phrase
- NCT04569591·RECRUITING·DDAVP for Pituitary Adenoma
Conditions: Cushing's Disease · Pituitary Adenoma·Matched via name phrase
- NCT07095517·RECRUITING·Pathways, Risk Factors, and mOleculeS to Prevent Early-onset Colorectal Tumors
Conditions: Colorectal Cancer Prevention · Colorectal Adenoma·Matched via name phrase
- NCT07090291·RECRUITING·China Colorectal Cancer Screening Trial 1 (C-Cost1)
Conditions: Colorectal Cancer · Advanced Adenoma·Matched via name phrase
- NCT06398418·RECRUITING·R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients With Solid Tumors
Conditions: Solid Tumor, Adult · Solid Tumor · Melanoma · Basal Cell Cancer·Matched via name phrase
Observational and natural-history studies
2 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
Recruiting or not-yet-recruiting
- NCT00461188·RECRUITING·Genetics of Endocrine Tumours - Familial Isolated Pituitary Adenoma - FIPA
Conditions: Acromegaly · Gigantism · Familial Isolated Pituitary Adenoma · FIPA·Matched via name phrase
- NCT06523582·RECRUITING·Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients
Conditions: Neuroendocrine Neoplasm · Neuroendocrine Neoplasm of Gastrointestinal Tract · Neuroendocrine Neoplasm of Lung · Thymic Neuroendocrine Neoplasm·Matched via name phrase
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 0 · after dedupe 0 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 0 · dropped 0 · fetched 2026-07-30
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Familial isolated pituitary adenoma — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Familial isolated pituitary adenoma"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Familial isolated pituitary adenoma"
Study-type breakdown: 0 interventional · 2 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"adenoma"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Synonyms dropped by stoplist: FIPA
Confidence reasoning
- Preferred label is multi-word and distinctive
- 1 synonym(s) dropped by stoplist (may under-count)
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T13:13:30.545Z
